PHASE IB/II STUDY OF LENALIDOMIDE, RITUXIMAB, HIGH‐DOSE METHOTREXATE (R2‐MTX) REGIMEN, FOLLOWED BY LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA
Open Access
- 17 June 2021
- journal article
- abstracts
- Published by Wiley in Hematological Oncology
- Vol. 39 (S2)